Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARRY-ON study of atezolizumab continuation with platinum-etoposide rechallenge in sensitive-relapse small cell lung cancer
2024-511945-20-00Phase 2Authorised
- Sponsor
- GOIRC
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by GOIRC. Primary endpoint: overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-511945-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511945-20-00.